HDAC9 and Huntington disease: Pimelic diphenylamide HDAC inhibitors have received renewed attention in recent years due to the efficacy of compounds from this series in the amelioration of phenotypes in Friedreich’s ataxia (FRDA) and Huntington’s disease (HD) cell and mouse models [1].